Blueprint Medicines To Present Preliminary Data From Ongoing Phase 1 Clinical Trial For BLU-285 In Advanced Systemic Mastocytosis At 2016 ASH Annual Meeting

CAMBRIDGE, Mass., Nov. 3, 2016 /PRNewswire/ --Blueprint Medicines Corporation(NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced that preliminary data from its Phase 1 clinical trial evaluating BLU-285 for the treatment of advanced systemic mastocytosis (SM) will be presented in an oral presentation at the 2016 American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, December 3-6, 2016. In addition, an abstract detailing SM patients' experiences with Mast Cell Connect, the first patient-reported registry for mastocytosis, and an abstract submitted by Blueprint Medicines' collaborator Dr. Andreas Reiter from the Department of Hematology and Oncology at the University Medical Centre Mannheim, Germany, detailing preclinical data on the inhibitory effects of BLU-285 on cells derived from patients with advanced SM, have been accepted for presentation at ASH.

Blueprint Medicines logo

The accepted abstracts are listed below and are now available online on the ASH conference website:

Oral Presentation:

Date & Time: Sunday, December 4, 2016 at 5:00 p.m. PT (8:00 p.m. ET)
Presentation Title: Preliminary Safety and Activity in a Phase 1 Study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM)
Session Title: 634. Myeloproliferative Syndromes: Clinical: Clinical Trials with Agents Other Than JAK Inhibitors
Abstract Number: 477
Location: Marriot Marquis San Diego Marina, Marriott Grand Ballroom Salons 8-9

Poster Presentations:

Date & Time: Saturday, December 3, 2016 from 5:30 p.m.7:30 p.m. PT (8:30 p.m.10:30 p.m. ET)
Presentation Title: Inhibitory Effects of Midostaurin and BLU-285 on Myeloid Progenitor Cells Derived from Patients with Multi-Mutated KIT D816V+ Advanced Systemic Mastocytosis
Session Title
: 635. Myeloproliferative Syndromes: Basic Science: Poster I
Abstract Number: 1964
Location: San Diego Convention Center, Hall GH

Date & Time: Monday, December 5, 2016 from 6:00 p.m.8:00 p.m. PT (9:00 p.m.11:00 p.m. ET)
Presentation Title: Systemic Mastocytosis Patient Experience from Mast Cell Connect, the First Patient-Reported Registry for Mastocytosis
Session Title: 904. Outcomes Research”Malignant Conditions: Poster III
Abstract Number: 4783
Location: San Diego Convention Center, Hall GH

Conference Call information

Blueprint Medicines will host a conference call and webcast on Monday, December 5, 2016 at 8:00 a.m. ET to discuss the BLU-285 clinical data presented at ASH. To participate in the conference call, please dial 855-728-4793 (domestic) or 503-343-6666 (international) and refer to conference ID 10777452. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of Blueprint Medicines' website at A replay of the webcast will be available approximately two hours after the conference call and will be available for 30 days following the call.

About Blueprint Medicines

Blueprint Medicinesis developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company's approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases.Blueprint Medicinesis advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please

Logo -

To view the original version on PR Newswire, visit:

SOURCE Blueprint Medicines Corporation

Comments on BPMC stock

Do share this awesome post